Citations

Clear

6728 citation(s) found for "Li, Mark".

PET Imaging of Osteomyelitis with [68Ga]Ga-BP
Pandey, Mukesh K., Bansal, Aditya, Sharma, Shalini, Karau, Melissa J. , Raval, Yash S. , Broski, S. M., Patel, Robin , Nathan, Mark, Lowe, Val J., Pandey, Mukesh K. , Broski, Stephen M. , Patel, Robin , Broski, Stephen M , Pandey, Mukesh K , Raval, Yash S. , Bansal, Aditya , Lowe, Val J. , Karau, Melissa

Mayo Clinic

Chemical & Biomedical Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/cbmi.6c00082 | PMID 42953237 Get It

Abstract A low-cost, easy-to-adopt noninvasive imaging modality for differentiating bacterial infection from inflammation is desirable to accurately diagnose bacterial infections. Herein, a bacteria-specific PET probe, [68Ga]Ga-BP, was developed and evaluated in rat models of foreign body-associated osteomyelitis induced by methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae and was directly compared with sterile inflammation and uninstrumented uninfected controls. [68Ga]Ga-BP-based imaging of MRSA-infected tibiae was also compared to [68Ga]Ga-citrate and [18F]FDG. After iron depletion, dynamic PET/CT imaging was performed at 15–120 min postinjection of radiotracers, followed by assessment of ex vivo biodistribution. [68Ga]Ga-BP successfully detected tibial infection and demonstrated >6-fold higher uptake in infected tibiae with all three bacterial species versus contralateral tibiae via PET imaging. [68Ga]Ga-BP outperformed [68Ga]Ga-citrate and [18F]FDG in identifying MRSA infection. [68Ga]Ga-BP represents a promising, noninvasive PET imaging agent for direct bacterial detection and bacterial infection treatment monitoring.
Size-dependent alterations in phrenic motor neuron perineuronal nets following cervical spinal hemisection
Cheung, Sang Won , Fogarty, Matthew J. , Zhan, Wen-Zhi, Bellingham, Mark C. , Noakes, Peter G. , Sieck, Gary C. , Bellingham, Mark C , Sieck, Gary , Fogarty, Matthew J , Zhan, Wen‐Zhi

Mayo Clinic

Journal of Neurophysiology | June 8, 2026 | Volume: 136 | Issue: 1 | Pages: 180-190

10.1152/jn.00033.2026 | PMID 42258373 Get It

Neuroplastic changes in phrenic motor neurons that underlie recovery from spinal cord injury may be mediated by perineuronal nets. We show that changes in perineuronal nets around phrenic motor neurons occur within 7 days after cervical spinal cord injury, and that the increase in perineuronal nets around larger phrenic motor neurons was more pronounced. These changes are consistent with substantial reorganization of the neural network onto intact phrenic motor neurons following cervical spinal cord injury.
Lysosomal lipid metabolism promotes tumor cell invasion through local energetics and membrane lipid remodeling
Nooren, Roseanne E. , Johnson, Katherine M. , Marley, Maxwell G., Rozeveld, Cody N., Gibbard, D., Correa, Zinnarky K Ortiz, Espe, Tianna, Hitosugi, Taro , Liu, Jun, McNiven, Mark A, Gibbard, Daniel F., Gedik, Mustafa Emre, Brownfield, Douglas G , Razidlo, Gina L , Johnson, Katherine M., Ortiz‐Correa, Zinnarky K., Gedik, Mustafa Emre , Lanza, Ian R. , Brownfield, Douglas , McNiven, Mark A. , Razidlo, Gina L.

Mayo Clinic

No container title available | June 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.729624 | PMID 42282716 Get It

Abstract Metabolic vulnerabilities in cancer have been targeted primarily to suppress tumor growth, but less is known about the metabolic requirements for tumor cell invasion. Here we report that lipid catabolism by cytosolic and lysosomal lipases supports pancreatic cancer cell invasion through both overlapping and distinct functional and metabolic mechanisms. Lysosomal acid lipase (LAL)-dependent lipid droplet catabolism promotes invadopodia formation and stabilization, enabling extracellular matrix degradation. In addition to modulating cellular energetics, lipidomics revealed that lipid droplet catabolism regulates cholesterol and membrane phospholipid levels. Using spatially resolved biosensors and cholesterol imaging, we found that lysosomal lipid catabolism occurs at invadopodia and sustains local ATP and membrane cholesterol. These findings identify spatially organized lipid catabolism as a mechanism that couples local energetics and membrane remodeling during the earliest steps of pancreatic cancer cell invasion.
OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial
Khanna, D, Korman, David S., Mease, Philip, Griffith, Melissa, Carpintero, Maria , Wener, Mark H. , Kramer, Neil , Schett, G, Mayes, Maureen D., Melton, Alexis, Handy, Whitney, Ou, San-San, Jarugula, Praneeth , Ide, Takafumi , Harnois, Melissa, Thorpe, Jerill , Koegel, Ashley, Wiesendanger, Margrit, Harnois, Melissa J. , Khanna, Dinesh , Majithia, Vikas , Bernstein, Elana J. , Mease, Philip J. , Simon, David , Schett, Georg , Gómez‐García, Ignacio , Mayes, Maureen D. , Desai, Alisha, Handy, Whitney, Ou, San‐San , Ide, Takafumi, Koegel, Ashley K., Wiesendanger, Margrit

Mayo Clinic

Oral Communications | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: A61-A63

10.1136/jsrd-2026-sswc.57 Get It

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions
Schreck, Karisa C, Fuente, Macarena I de la, Fat, Mary Jane Lim, Maas, S L, Levy, Jean M Mulcahy, Lombardi, G , Perrault, Sébastien, Petritsch, Claudia , Aldape, Kenneth, Chang, Susan M, Holdhoff, Matthias, Kazda, Tomas, Rhun, Emilie Le, Minniti, Giuseppe, Mueller, Sabine, Preusser, M, Smits, Marion, Weller, Michael, Wen, Patrick Y, Bent, Martin van den, Geurts, Marjolein, Lombardi, Giuseppe , Maas, Sybren L. N. , Schreck, Karisa C. , Levy, Jean M. Mulcahy , Chang, Susan M. , Duerinck, Johnny , Holdhoff, Matthias , Kazda, Tomáš , Rhun, Émilie Le , Minniti, Giuseppe , Mishra, Mark V. , Mueller, Sabine , Padovan, Marta , Preusser, Matthias , Smits, Marion , Weller, Michael , Bent, Martin J. van den , Geurts, Marjolein

Mayo Clinic

Neuro-Oncology | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag135 | PMID 42261252 Get It

Abstract Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
The effect of rocking speed and cell inoculation density on hepatic spheroid size: A simple method for size modulation
Megaly, Michael , Tobolt, Diane, Chen, A. W. , Namsrai, Bat‐Erdene, Fisher, Benjamin , Ramesh, Srivasupradha, Chimedtseren, Anudari, Nyberg, Scott L. , Clemens, Dr Mark, Lee, Charles Y., Finger, Erik B. , Tobolt, Diane, Rao, Joseph Sushil , Ramesh, Srivasupradha, Bischof, John C , Finger, Erik B. , Megaly, Michael G

Mayo Clinic

Bioengineering & Translational Medicine | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/btm2.70154 | PMID 42835954 Get It

Abstract Hepatic spheroids are widely used in bioartificial liver (BAL) systems, hepatotoxicology, and pharmacology due to improved functional stability compared with monolayer cultures. However, many existing methods rely on specialized equipment or static platforms that limit scalability and dynamic culture applications. Primary rat hepatocytes were cultured as three‐dimensional spheroids using a rocker‐based suspension system. Spheroid formation was evaluated across a range of rocking speeds (7–18 cycles per minute [cpm]) and inoculation densities. Spheroid morphology was quantified over time using two‐dimensional imaging. Functional performance was assessed by urea and albumin production on days 1, 4, 7, and 10. Spheroid formation efficiency was evaluated using volumetric modeling. Mean spheroid diameter decreased from 199 ± 41 μm at 7 cpm to 80.2 ± 17.6 μm at 18 cpm. The spheroid area was significantly influenced by both culture day ( p < 0.0001) and rocker speed, with significant differences observed across speeds at all time points ( p < 0.001, days 1–7). Mean spheroid area at 10 cpm was 13,750 ± 9051 μm 2 (day 1), 26,730 ± 8658 μm 2 (day 4), and decreased to 22,526 ± 8705 μm 2 (day 7). Urea production differed across speeds (ANOVA, p = 0.043), with peak performance at 12 cpm (median 3.47 μg/μg DNA) compared to 7 cpm (median 0.11 μg/μg DNA). Albumin production was 1086.8 ng/μg DNA on day 1 and 1534.4 ng/μg DNA on day 10. Urea production was 0.62 μg/μg DNA on day 1 and 1.25 μg/μg DNA on day 10. Median hepatocyte incorporation was 86% (range 73%–116%) by day 4. This rocker‐based method provides a simple, low‐cost, and scalable approach for generating hepatic spheroids with tunable size distributions under dynamic conditions. The system supports progressive functional maturation and is compatible with established scale‐up strategies, supporting its potential for translational applications.
Incremental Prognostic Value of Subendocardial Myocardial Flow Reserve in Patients With Normal Perfusion
Lopez, Diana M. , Brown, Jenifer M. , Divakaran, Sanjay , Weber, Brittany , Hainer, Jon , Carre, Sylvain, Lemley, Mark , Ramirez, Giselle , Shanbhag, Aakash , Kavanagh, Paul, Liang, Joanna X. , Blankstein, Ron , Dorbala, S, Mason, Steve, Wopperer, Samuel , Rosamond, Thomas, Kwieciński, Jacek , Travin, Mark I. , Alexanderson, Erick, Packard, René R S, Feher, A, Sanghani, Rupa, deKemp, Robert A. , Berman, Daniel S. , Slomka, P J, Carli, Marcelo F. Di , Packard, René R. Sevag , Lopez, Diana M , Huck, Daniel , Weber, Brittany , Hainer, Jon , Lemley, Mark , Ramirez, Giselle , Shanbhag, Aakash , Kavanagh, Paul , Blankstein, Ron , Dorbala, Sharmila , Dey, Damini , Knight, Stacey , Le, Viet T , Wopperer, Samuel , Chareonthaitawee, Panithaya , Rosamond, Thomas L , Kwiecinski, Jacek , Miller, Robert J H , Slipczuk, Leandro , Carvajal-Juarez, Isabel , Packard, Rene R S , Al-Mallah, Mouaz H , Einstein, Andrew Jeffrey , Feher, Attila , Acampa, Wanda , Buechel, Ronny R , deKemp, Robert A , Berman, Daniel , Slomka, Piotr J , Di Carli, Marcelo F , Divakaran, Sanjay , Brown, Jenifer Michelle , Kavanagh, Paul , Dey, Damini , Knight, Stacey , Le, Viet T. , Mason, Steve, Chareonthaitawee, Panithaya , Miller, Robert J.H. , Slipczuk, Leandro , Alexanderson, Erick , Carvajal-Juarez, Isabel , Al‐Mallah, Mouaz H. , Sanghani, Rupa Mehta

Mayo Clinic

Circulation | June 4, 2026 | Volume: 154 | Issue: 3 | Pages: 212-222

10.1161/circulationaha.125.078816 | PMID 42237914 Get It

BACKGROUND: Although the prognostic utility of positron emission tomography (PET) myocardial flow reserve (MFR) is well established, emerging data suggest that reduced subendocardial flows also predict adverse outcomes. However, the incremental value of subendocardial MFR (MFR SE ) beyond transmural MFR (MFR TM ) remains unclear. METHODS: We studied patients in a multicenter PET registry with normal perfusion on stress/rest Rb-82 PET, excluding those with a previous history of coronary artery bypass surgery, heart transplantation, or left ventricular ejection fraction <40%. The optimal MFR SE cutoff for predicting major adverse cardiovascular events (MACEs; death, myocardial infarction [MI], revascularization, or heart failure [HF] hospitalization) was determined using Youden’s index. Patients were stratified into 3 groups: concordant-normal (MFR TM ≥2.0; MFR SE ≥2.1), discordant (low-MFR SE , normal MFR TM ), and abnormal MFR TM . Clinical outcomes were compared by MFR groups. RESULTS: Among 6603 patients (normal N=4103; discordant N=885; abnormal N=1615) the mean age was 66.3±12.4 years, and 54% were women. Compared with the concordant-normal group, patients with discordant low-MFR SE were older and more likely to have hypertension, diabetes, peripheral artery disease, and previous percutaneous coronary intervention. The median MFR TM for normal, discordant, and abnormal groups were 2.86, 2.15, and 1.72, respectively. Over a median follow-up of 4.9 years, 1661 MACE events occurred. Discordant low-MFR SE patients had a higher risk of MACE (hazard ratio [HR], 1.41; 95% CI, 1.22–1.64) and all-cause mortality (HR, 1.36; 95% CI, 1.14–1.61) compared with concordant-normal patients. The discordant group had an intermediate absolute risk of MACE, with an adjusted annualized event rate of 5.79% (95% CI, 5.10–6.49) compared with 3.99% (95% CI, 3.67–4.30; P <0.001) in the concordant-normal group and 8.35% (95% CI, 7.71–9.00; P <0.001) in the abnormal MFR TM group. CONCLUSIONS: Subendocardial MFR reveals clinically meaningful risk heterogeneity among patients with preserved transmural flow reserve, helping refine risk stratification beyond traditional PET metrics.
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Liu, Y H, Carter, Jodi M. , Ma, Yaohua, Deshmukh, Sachin K, Sledge, George W, Kachergus, Jennifer M, Shi, Ji , Gregory, Mark, Gong, Jingjing, Joensuu, H, Perez, EA, Stover, Daniel, Carey, Lisa, Sikov, William M. , Leon-Ferre, Roberto, Knutson, Keith L. , Boughey, Judy C, Ingle, J , Couch, Fergus J, Asmann, Yan W. , Goetz, Matthew P, Thompson, E Aubrey, Chumsri, Saranya, Liu, Yi , Liu, Yi , Wrangle, John M , Stover, Daniel G , Leon-Ferre, Roberto , Knutson, Keith L. , Ingle, James N. , Carter, Jodi , Balko, Justin M. , Kachergus, Jennifer M., Joensuu, Heikki , Perez, EA, Carey, Lisa, Boughey, Judy C. , Kalari, Krishna R. , Couch, Fergus J. , Goetz, Matthew P. , Thompson, E. Aubrey , Chumsri, Saranya

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 3, 2026 | Volume: 14 | Issue: 6 | Pages: e014020

10.1136/jitc-2025-014020 | PMID 42236117 Get It

Background Tumor-infiltrating lymphocytes (TILs) are established determinants of clinical outcomes in breast cancer. 1–6 While stromal TILs (sTILs) are commonly evaluated due to easier scoring and higher interobserver reproducibility, intraepithelial TILs may provide additional insights into anti-tumor immunity. 7 We aimed to comprehensively characterize immunotype-associated cellular landscapes in triple-negative breast cancer (TNBC) and identify features associated with clinical outcomes. Methods 212 TNBC tumors were classified into three immunotypes based on immune infiltrate location and density: immune desert (ID), immune excluded (IE), and immune inflamed (IN). 8 Single-cell spatial transcriptomics was performed on 75 tumors to define the cellular composition and functional states of the tumor microenvironment across immunotypes. Findings were validated and integrated with bulk RNA sequencing data and clinical outcome datasets from FinXX, CALGB-40603, I-SPY 2, and Real-World Clinico-Genomic Data (RWCGD) cohorts. Results Patients with IN tumors had significantly improved outcomes compared with ID tumors. Despite high sTILs, IE tumors showed poor outcomes similar to ID tumors. Single-cell spatial analysis revealed that ID and IE tumors exhibited reduced major histocompatibility complex I/II expression and fewer tumor-resident plasmacytoid dendritic cells (pDCs) compared with IN tumors, which were enriched for interferon-alpha (IFNα) and interferon-gamma (IFNγ) responses. High IFN response scores were associated with favorable outcomes across multiple therapy types in independent datasets. Deconvolution of RWCGD bulk RNA-seq data confirmed that pDC abundance correlated with improved outcomes specifically in hormone receptor–negative subtypes. Conclusions Our study highlights pDCs and IFN signaling as hallmarks of effective anti-tumor immunity in TNBC. Immunotype-based profiling underscores the limited prognostic value of sTILs alone in immune-excluded tumors and supports pDCs and IFN pathways as potential biomarkers for prognosis and therapeutic development in TNBC.
Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Uysal, Utku, Landazuri, Patrick , Patra, Sanjay, Crudele, Angela, Englot, Dario, Gavvala, Jay R., Tandon, Nitin, Pati, Sandipan , Kaye, Lesley , Ojemann, Steven, Barnett, Daniel, Neimat, Joseph, Palade, Adriana , Rahimpour, Shervin, Arain, Amir A., Cash, Sydney S., Salanova, Vicenta , Urban, Alexandra, Welch, W. Pete, Gonzalez-Martinez, Jorge A., Spencer, David, Rivera‐Cruz, Angélica , Dugan, Patricia, Fajardo, Marytery , Lallas, Matt, Odom, Nicole, Roland, Jarod L. , Willie, Jon T., Sheth, Sameer A., Skidmore, Christopher T., Drees, Cornelia , Parker, Jonathon, Szaflarski, Jerzy P. , Johnson, Lise, Norman, Jacob F. , Wingeier, Brett, Group, Nautilus Study, Group, Nautilus Study, Englot, Dario J. , Englot, Dario J , Richardson, Robert Mark , Van Gompel, Jamie J , Starnes, Keith , Ernst, Lia D , Amin, Ushtar , Roland, Jarod L , Goldman, Alica M , Wu, Chengyuan , Drees, Cornelia , Ganguly, Taneeta Mindy , Szaflarski, Jerzy , Johnson, Lise , Norman, Jacob F , Landazuri, Patrick , Burdette, David E. , Patra, Sanjay , Gavvala, Jay R. , Tandon, Nitin , Pati, Sandipan Bankim Behari , Kaye, Lesley C , Ojemann, Steven , Neimat, Joseph S. , Rahimpour, Shervin , Arain, Amir M. , Cash, Sydney S. , Urban, Alexandra , González-Martínez, Jorge , Gompel, Jamie J. Van , Ernst, Lia , Dugan, Patricia , Jobst, Barbara C. , Willie, Jon T , Sheth, Sameer A. , Goldman, Alica M. , Skidmore, Christopher , Wu, Chengyuan , Parker, Jonathon J. , Ganguly, Taneeta M. , Ghatan, Saadi , Wingeier, Brett , Seale, Cairn G. , Morrell, Martha J.

Mayo Clinic

Epilepsia | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70321 | PMID 42233958 Get It

Abstract Objective This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.
Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.
Mendenhall, Nancy P., Bryant, C. A., Katz, Aaron, Morris, Christopher G. , Crisp, Amy M., Odedina, Folakemi, Michalski, Jeff M., Slater, J.D., Choi, Seungtaek, Gayar, H., Sinesi, Christopher, Zlotecki, Robert A., Marshall, David T. , Waddle, Mark R. , Hoppe, Bradford, SHOWALTER, TIMOTHY, DiBiase, Steven J., Lee, W Robert, Chen, Ronald C., Lee, W. Robert , Mendenhall, Nancy P. , Bryant, Curtis, Katz, Aaron J., Crisp, Amy M , DeWees, T.A. , Michalski, Jeff M. , Choi, Seungtaek, Sinesi, Christopher, Showalter, Timothy N. , DiBiase, Steven J. , Chen, Ronald C.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba5012 Get It

LBA5012 Background: There is a critical evidence gap on the relative benefits and harms of proton therapy (PT) compared with photon-based intensity-modulated radiation therapy (IMRT) in prostate cancer. Herein we report early results from COMPPARE, a non-randomized comparative study of outcomes with PT and IMRT in prostate cancer. Methods: Between 2018-2022, 2524 patients from 51 facilities (28 PT and 23 IMRT) enrolled in COMPPARE, including 1501 treated with PT and 1023 treated with IMRT, and were followed prospectively. Treatment naïve patients with localized prostate cancer except those with very high-risk disease were eligible. Treatment was pragmatic with daily standard fractionation (1.8-2.1 Gy) and moderate hypofractionation (2.4-3.1 Gy) permitted. Use of rectal spacers and androgen deprivation were at physician discretion. Patient-reported quality of life data and treatment team-reported toxicity and disease control outcomes were collected at baseline and pre-specified time intervals via VisionTreeOptimalCare; treatment planning and delivery data were collected via the Advanced Treatment Consortium. We analyzed 1404 PT patients and 939 IMRT patients. We report the early primary endpoint of the study, a comparison of patient reported bowel urgency and bowel frequency at 2-years using the EPIC tool, and the secondary endpoints of 2-year CTCAE v5 ≥ grade 2 gastrointestinal toxicity outcomes and 3-year freedom from biochemical progression (FFBP) results reported by the study teams. Results: Study sample size was targeted at 1,500 PT patients and 1,000 IMRT patients, and median follow-up time was 4.0 years. The primary endpoint and secondary toxicity 2-year endpoints focused on the alternative hypothesis of PT superiority. All results include inverse probability of treatment weighting. Using generalized linear mixed effects models, we found there to be no significant difference in EPIC bowel urgency scores (p = 0.324) or bowel frequency scores (p = 0.514) between PT and IMRT cohorts over time up to the 2-year endpoint. For grade 2 gastrointestinal toxicity, the 2-year cumulative incidence was 5.2% for PT and 5.6% for IMRT. Gray’s Test for competing risks showed a hazard ratio (HR) of 0.91 [95% confidence interval (CI): 0.65-1.28, p = 0.6] for PT versus IMRT. The exploratory non-inferiority endpoint of 3-year FFBP was 98.0% for PT and 97.9% for IMRT, and Gray’s Test showed a HR of 0.95 (95% CI: 0.52-1.71, p = 0.90). Conclusions: Analysis of early results of COMPPARE show no significant differences between PT and IMRT in patient reported bowel frequency and urgency, grade ≥2 gastrointestinal toxicity, or FFBP. Assessment of long-term disease control, late toxicity and secondary malignancy will require longer follow-up. Clinical trial information: NCT03561220 .